FRAZER, Pa., Oct. 14 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that a Risk Evaluation and Mitigation Strategy (REMS) for its antiepileptic medication GABITRIL(R) (tiagabine hydrochloride) has been approved by the U.S. Food and Drug Administration (FDA).

FRAZER, Pa., April 5 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that it has completed its previously announced acquisition of biotechnology company Ception Therapeutics, Inc.

FRAZER, Pa., Nov. 4 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that its Research and Development Day in New York City, to be held on November 10, 2009, will be webcast live on the investor relations section of its website at http://www.cephalon.com.

FRAZER, Pa., July 31 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that Craig C. Phillips has been appointed as Vice President and General Manager of the Oncology Business Unit. In this role, Phillips will have responsibility for managing all aspects of the U.S.

Company to Submit a Supplemental New Drug Application to Expand the NUVIGIL(R) Label FRAZER, Pa., April 6 /PRNewswire-FirstCall/ -- Cephalon, Inc.